Glaukos Corporation (GKOS) Stock
GKOS Key Statistics
About Glaukos Corporation
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
CEO: Thomas William Burns. Company website
GKOS — Frequently Asked Questions
What is the GKOS stock price today?
Glaukos Corporation (GKOS) trades at $247.16, up 4.64% on the day, as of Nov 12, 2026 09:30 UTC.
What is Glaukos Corporation's market cap?
Glaukos Corporation has a market capitalisation of $14.63B, calculated from the live GKOS share price and shares outstanding.
What is the P/E ratio of GKOS?
GKOS has no meaningful price-to-earnings ratio: Glaukos Corporation lost $2.94 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Glaukos Corporation make?
Glaukos Corporation generated revenue of $690.33M over the trailing twelve months, which puts the stock at 21.19 times sales.
What is the 52-week range for GKOS?
GKOS has traded between $80.91 and $255.19 over the past 52 weeks, and the last price is 3.1% below that high.
Is Glaukos Corporation profitable?
No. Glaukos Corporation is loss-making, with a net margin of -24.60% over the trailing twelve months.
What is the analyst price target for GKOS?
Wall Street analysts rate GKOS Buy, with an average price target of $218.70, 11.5% below the current price.
What sector is Glaukos Corporation in?
Glaukos Corporation is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of Glaukos Corporation?
Thomas William Burns is the chief executive of Glaukos Corporation, which employs 1,094 people.
Where can I track GKOS in real time?
QFI Terminal shows GKOS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See GKOS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open GKOS in Terminal See plans